These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 22768894

  • 1. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.
    Pscherer S, Larbig M, von Stritsky B, Pfützner A, Forst T.
    J Diabetes Sci Technol; 2012 May 01; 6(3):634-40. PubMed ID: 22768894
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J, Pegelow K, Bramlage P.
    Vasc Health Risk Manag; 2013 May 01; 9():711-7. PubMed ID: 24259985
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM, Jung CH, Lee SH, Kim SW, Song KH, Kim SG, Kim JH, Cho YM, Park TS, Ku BJ, Koh G, Kim DM, Lee BW, Park JY.
    Diabetes Metab J; 2019 Aug 01; 43(4):432-446. PubMed ID: 31237133
    [Abstract] [Full Text] [Related]

  • 4. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S, Ohta A, Kato H, Sada Y, Nagai Y, Kondo A, Sasaoka T, Tanaka Y.
    Endocr J; 2014 Aug 01; 61(12):1213-20. PubMed ID: 25231694
    [Abstract] [Full Text] [Related]

  • 5. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.
    Forst T, Larbig M, Hohberg C, Forst S, Diessel S, Borchert M, Roth W, Pfützner A.
    Diabetes Obes Metab; 2010 May 01; 12(5):437-41. PubMed ID: 20415692
    [Abstract] [Full Text] [Related]

  • 6. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A.
    Diabetes Metab Res Rev; 2014 Oct 01; 30(7):582-9. PubMed ID: 24459063
    [Abstract] [Full Text] [Related]

  • 7. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 01; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 8. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P, Malone JK.
    Diabet Med; 2006 Jul 01; 23(7):743-9. PubMed ID: 16842478
    [Abstract] [Full Text] [Related]

  • 9. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A.
    Horm Metab Res; 2007 Nov 01; 39(11):826-9. PubMed ID: 17992639
    [Abstract] [Full Text] [Related]

  • 10. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
    Ohkura T, Inoue K, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Ohkura H, Kato M, Yamamoto K, Taniguchi S.
    BMC Res Notes; 2013 Nov 11; 6():453. PubMed ID: 24215809
    [Abstract] [Full Text] [Related]

  • 11. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.
    Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, Hanefeld M.
    Acta Diabetol; 2013 Aug 11; 50(4):587-95. PubMed ID: 23430192
    [Abstract] [Full Text] [Related]

  • 12. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.
    Ohta A, Kato H, Murayama K, Hashimoto E, Murakami M, Nishine A, Ohshige T, Sada Y, Asai S, Kawata T, Nagai Y, Katabami T, Tanaka Y.
    Endocr J; 2014 Aug 11; 61(1):13-8. PubMed ID: 24064478
    [Abstract] [Full Text] [Related]

  • 13. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.
    Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T.
    Diabetes Technol Ther; 2006 Jun 11; 8(3):375-84. PubMed ID: 16800759
    [Abstract] [Full Text] [Related]

  • 14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Ann Med; 2016 Jun 11; 48(4):224-34. PubMed ID: 26982210
    [Abstract] [Full Text] [Related]

  • 15. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
    Takahashi M, Shibasaki M, Echizen H, Kushiyama A.
    PLoS One; 2020 Jun 11; 15(7):e0236603. PubMed ID: 32706828
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, Xu L, Hanson ME, Engel SS, Shankar RR.
    J Diabetes; 2017 Jul 11; 9(7):667-676. PubMed ID: 27502307
    [Abstract] [Full Text] [Related]

  • 17. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T, Dworak M, Berndt-Zipfel C, Löffler A, Klamp I, Mitry M, Pfützner A.
    Diabetes Obes Metab; 2013 Jun 11; 15(6):576-9. PubMed ID: 23384119
    [Abstract] [Full Text] [Related]

  • 18. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus.
    Dailey G, Aurand L, Stewart J, Ameer B, Zhou R.
    J Diabetes; 2014 Mar 11; 6(2):176-83. PubMed ID: 23931125
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
    Wang F, He Y, Zhang R, Zeng Q, Zhao X.
    Medicine (Baltimore); 2017 Sep 11; 96(36):e7638. PubMed ID: 28885325
    [Abstract] [Full Text] [Related]

  • 20. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE.
    J Diabetes Complications; 2014 Sep 11; 28(3):386-92. PubMed ID: 24650952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.